Sirolimus-induced acneiform eruption.
Sirolimus is a new immunosuppressive agent used to prevent rejection in renal allograft recipients in order to reduce the need of potentially nephrotoxic calcineurin inhibitors (cyclosporine, tacrolimus). The cutaneous side effects of sirolimus are not well known and they may have been underestimated. We report 2 cases of follicular acneiform eruptions induced by sirolimus in renal allograft recipients. This dermatologic complication was severe and difficult to treat, and resolved only after discontinuation of sirolimus.
Kunzle
N
N
Department of Dermatology and Venerology, DHURDV, Lausanne, Switzerland.
Venetz
J-P
JP
Pascual
M
M
Panizzon
R G
RG
Laffitte
E
E
D017486:Acneiform Eruptions / Q000139:chemically induced*; D000328:Adult; D003875:Drug Eruptions / Q000209:etiology*; D005148:Facial Dermatoses / Q000139:chemically induced*; D005260:Female; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D020123:Sirolimus / Q000009:adverse effects*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D020123:Sirolimus